144 related articles for article (PubMed ID: 16459149)
1. RETRACTED: Selective targeting of checkpoint kinase 1 in tumor cells with a novel potent oncolytic adenovirus.
Gao Q; Zhou J; Huang X; Chen G; Ye F; Lu Y; Li K; Zhuang L; Huang M; Xu G; Wang S; Ma D
Mol Ther; 2006 May; 13(5):928-937. PubMed ID: 16459149
[TBL] [Abstract][Full Text] [Related]
2. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
[TBL] [Abstract][Full Text] [Related]
3. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
4. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
5. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
6. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
[TBL] [Abstract][Full Text] [Related]
7. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
8. Augmenting the antitumor effect of TRAIL by SOCS3 with double-regulated replicating oncolytic adenovirus in hepatocellular carcinoma.
Wei RC; Cao X; Gui JH; Zhou XM; Zhong D; Yan QL; Huang WD; Qian QJ; Zhao FL; Liu XY
Hum Gene Ther; 2011 Sep; 22(9):1109-19. PubMed ID: 21361790
[TBL] [Abstract][Full Text] [Related]
9. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
10. Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery.
Kwon OJ; Kang E; Kim S; Yun CO
J Control Release; 2011 Oct; 155(2):317-25. PubMed ID: 21699929
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
[TBL] [Abstract][Full Text] [Related]
12. Use of microRNA Let-7 to control the replication specificity of oncolytic adenovirus in hepatocellular carcinoma cells.
Jin H; Lv S; Yang J; Wang X; Hu H; Su C; Zhou C; Li J; Huang Y; Li L; Liu X; Wu M; Qian Q
PLoS One; 2011; 6(7):e21307. PubMed ID: 21814544
[TBL] [Abstract][Full Text] [Related]
13. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells.
Gao Q; Huang X; Tang D; Cao Y; Chen G; Lu Y; Zhuang L; Wang S; Xu G; Zhou J; Ma D
Apoptosis; 2006 Oct; 11(10):1789-800. PubMed ID: 16927022
[TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells deliver and release conditionally replicative adenovirus depending on hepatic differentiation to eliminate hepatocellular carcinoma cells specifically.
Yuan X; Zhang Q; Li Z; Zhang X; Bao S; Fan D; Ru Y; Dong S; Zhang Y; Zhang Y; Ye Z; Xiong D
Cancer Lett; 2016 Oct; 381(1):85-95. PubMed ID: 27450327
[TBL] [Abstract][Full Text] [Related]
15. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
16. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.
Rojas JJ; Guedan S; Searle PF; Martinez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R
Mol Ther; 2010 Nov; 18(11):1960-71. PubMed ID: 20808288
[TBL] [Abstract][Full Text] [Related]
17. Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.
Ma B; Wang Y; Zhou X; Huang P; Zhang R; Liu T; Cui C; Liu X; Wang Y
J Cancer Res Clin Oncol; 2015 Mar; 141(3):419-29. PubMed ID: 25240826
[TBL] [Abstract][Full Text] [Related]
18. The oncolytic adenovirus targeting to TERT and RB pathway induced specific and potent anti-tumor efficacy in vitro and in vivo for hepatocellular carcinoma.
Zhang W; Cai R; Luo J; Wang Y; Cui Q; Wei X; Zhang H; Qian C
Cancer Biol Ther; 2007 Nov; 6(11):1726-32. PubMed ID: 18281783
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus-mediated transfer of the antisense chk2 selectively inhibits tumor growth in vitro and in vivo.
Chen G; Zhou J; Gao Q; Huang X; Li K; Zhuang L; Huang M; Xu G; Wang S; Lu Y; Ma D
Cancer Gene Ther; 2006 Oct; 13(10):930-9. PubMed ID: 16741520
[TBL] [Abstract][Full Text] [Related]
20. Co-abrogation of Chk1 and Chk2 by potent oncolytic adenovirus potentiates the antitumor efficacy of cisplatin or irradiation.
Ye F; Yang Z; Liu Y; Gong D; Ji T; Wang J; Xi B; Zhou J; Ma D; Gao Q
Cancer Gene Ther; 2014 May; 21(5):209-17. PubMed ID: 24853623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
